Timely Administration of IV Magnesium Sulfate in Patients With a Moderate Asthma Exacerbation
RecruitingEarly phase 1
Who can join
Ages 5 to 17 · All sexes
Full eligibility criteria
Inclusion Criteria: * Ages 5-17 years old * Presents to the ED with a respiratory score in the "Moderate" range (6 * Parent(s)/Caregiver(s) speak English Exclusion Criteria: * Patients with chronic medical conditions including chronic pulmonary disease (other than asthma), cerebral palsy, congenital heart disease, tracheostomy dependent, myasthenia gravis patients * Patients who are pregnant * Parent(s)/Caregiver(s) do not speak English
About the study
This study aims to identify whether early administration of magnesium sulfate in moderate asthma exacerbations can potentially avoid admission, decrease length of stay in the emergency department (ED), decrease length of stay (LOS) in the general hospital floor vs pediatric intensive care unit (PICU), and decrease the need for respiratory support.
What is being tested
- Magnesium Sulfate within the first hour (drug)
- No Magnesium sulfate within the first hour (other)
Sponsor: University of Oklahoma · Participants: 100 · Started: Nov 30, 2023
Contact the study team
- Ryan McKee, MD · Phone: 4056308997
- Jaclyn Urquiola Sorzano, DO · Phone: 7863906297
Official record on ClinicalTrials.gov — NCT06137040
Locations in the U.S.
| Oklahoma | Oklahoma Children's Hospital, Oklahoma City |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.